Curated News
By: NewsRamp Editorial Staff
August 18, 2026
Freyja Healthcare Wins FDA Clearance for VereSee Mini Laparoscope
TLDR
- Freyja Healthcare's VereSee gains FDA clearance, giving early adopters a competitive edge in minimally invasive surgery with superior visualization.
- VereSee integrates a 2mm laparoscope with VisualEntry for direct visualization during entry, potentially reducing the need for additional scopes.
- This advancement enhances patient safety by allowing surgeons to see anatomy during entry, potentially reducing complications and improving outcomes.
- A tiny 2mm scope that lets surgeons see while entering the abdomen—a novel approach that may change laparoscopic surgery.
Impact - Why it Matters
This news matters because it introduces a novel approach to laparoscopic surgery that could enhance patient safety and procedural efficiency. By providing surgeons with direct visualization during the critical entry phase, VereSee may reduce the risk of complications associated with blind entry, such as vascular or bowel injury. Additionally, the device's dual functionality as a miniature laparoscope could streamline surgical workflows, potentially reducing procedure time and costs. For patients, this could translate to fewer complications and faster recovery. For healthcare systems, it offers a cost-effective solution that integrates into existing practices, making advanced visualization more accessible.
Summary
Framingham, MA-based medical device company Freyja Healthcare, LLC has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its second-generation Mini Laparoscope with VisualEntry™ System, marketed as VereSee™. This clearance marks a significant step in the company's mission to enhance visualization during the earliest stages of minimally invasive surgery. VereSee combines a miniature 2mm laparoscope with the VisualEntry™ System, allowing surgeons to visualize anatomy during the entry process—a departure from conventional methods where initial abdominal access may be performed without direct visualization. The device is designed to provide visualization from the moment of entry and can also serve as a standard miniature laparoscope for the remainder of the procedure, potentially eliminating the need for an additional scope. The system integrates single-use entry components with reusable visualization technology, aiming to fit seamlessly into existing surgical workflows while offering a practical economic model for healthcare providers. The FDA clearance, obtained through the 510(k) premarket pathway, classifies VereSee as a Class II Endoscope and Accessories device. Freyja Healthcare's CEO, Mike MacKinnon, emphasized the importance of enabling surgeons to see when it matters most, and founder Jon I. Einarsson, MD, highlighted the potential to fundamentally change how surgeons approach access and advance miniaturized laparoscopic visualization. With this clearance, the company plans to commence commercial introduction, expanding availability to hospitals, ambulatory surgical centers, and surgeons. Freyja Healthcare focuses on developing innovative solutions for minimally invasive surgery and women's health, and this product represents a key advancement in their portfolio.
Source Statement
This curated news summary relied on content distributed by 24-7 Press Release. Read the original source here, Freyja Healthcare Wins FDA Clearance for VereSee Mini Laparoscope
